COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF CYTOMEGALOVIRUS

摘要

The present invention provides novel anti-cytomegalovirus antibodies and related compositions and methods. These antibodies may be used in the diagnosis, prevention, and treatment of cytomegalovirus infection.

主权项

1. An isolated anti-CMV antibody or fragment thereof, wherein said antibody comprises:
I: (a) a VH region comprising
(i) a VH CDR1 region comprising the amino acid sequence of SNHGIH (SEQ ID NO: 36);(ii) a VH CDR2 region comprising the amino acid sequence of VISSDGDDDRYADSVKG (SEQ ID NO: 37);(iii) a VH CDR3 region comprising the amino acid sequence of DGRCGEPKCYSGLPDY (SEQ ID NO: 38); and (b) a VL region comprising
(i) a VL CDR1 region comprising the amino acid sequence of RASQSVGGYLA (SEQ ID NO: 43);(ii) a VL CDR2 region comprising the amino acid sequence of DASNRAT (SEQ ID NO: 44);(iii) a VL CDR3 region comprising the amino acid sequence of LQRNTWPPLT (SEQ ID NO: 45); II: (a) a VH region comprising
(i) a VH CDR1 region comprising the amino acid sequence of SNYGMH (SEQ ID NO: 48);(ii) a VH CDR2 region comprising the amino acid sequence of VISSDGSNEHYADSVKG (SEQ ID NO: 49);(iii) a VH CDR3 region comprising the amino acid sequence of DGRCPDVNCYSGLIDY (SEQ ID NO: 50); and (b) a VL region comprising
(i) a VL CDR1 region comprising the amino acid sequence of RASQSVGRYLA (SEQ ID NO: 53);(ii) a VL CDR2 region comprising the amino acid sequence of DASNRAT (SEQ ID NO: 44);(iii) a VL CDR3 region comprising the amino acid sequence of QQRSNWPPLT (SEQ ID NO: 54); III: (a) a VH region comprising
(i) a VH CDR1 region comprising the amino acid sequence of SSNGIH (SEQ ID NO: 57);(ii) a VH CDR2 region comprising the amino acid sequence of VISSDANDKQYADSVKG (SEQ ID NO: 58);(iii) a VH CDR3 region comprising the amino acid sequence of DGTCSGGNCYSGLIDY (SEQ ID NO: 59); and (b) a VL region comprising
(i) a VL CDR1 region comprising the amino acid sequence of RASQSVGGYLA (SEQ ID NO: 43);(ii) a VL CDR2 region comprising the amino acid sequence of ASIRAT (SEQ ID NO: 64);(iii) a VL CDR3 region comprising the amino acid sequence of HQRSNWPPLT (SEQ ID NO: 65); IV: (a) a VH region comprising
(i) a VH CDR1 region comprising the amino acid sequence of SNHGIH (SEQ ID NO: 36);(ii) a VH CDR2 region comprising the amino acid sequence of VISKDGTNAHYADSVRG (SEQ ID NO: 68);(iii) a VH CDR3 region comprising the amino acid sequence of EGRCIEENCYSGQIDY (SEQ ID NO: 69); and (b) a VL region comprising
(i) a VL CDR1 region comprising the amino acid sequence of RASQSVGRYMA (SEQ ID NO: 74);(ii) a VL CDR2 region comprising the amino acid sequence of DASIRAT (SEQ ID NO: 75);(iii) a VL CDR3 region comprising the amino acid sequence of QQRSSWPPLT (SEQ ID NO: 76); V: (a) a VH region comprising
(i) a VH CDR1 region comprising the amino acid sequence of SNHGIH (SEQ ID NO: 36);(ii) a VH CDR2 region comprising the amino acid sequence of VISKDGTNAHYADSVRGR (SEQ ID NO: 79);(iii) a VH CDR3 region comprising the amino acid sequence of EGRCIEEKCYSGQIDY (SEQ ID NO: 80); and (b) a VL region comprising
(i) a VL CDR1 region comprising the amino acid sequence of RASQSVGRYMA (SEQ ID NO: 74);(ii) a VL CDR2 region comprising the amino acid sequence of DASIRAT (SEQ ID NO: 75);(iii) a VL CDR3 region comprising the amino acid sequence of QQRSSWPPLT (SEQ ID NO: 76); VI: (a) a VH region comprising
(i) a VH CDR1 region comprising the amino acid sequence of SDYGMH (SEQ ID NO: 85);(ii) a VH CDR2 region comprising the amino acid sequence of VISKDGTNTHYADSVRG (SEQ ID NO: 86);(iii) a VH CDR3 region comprising the amino acid sequence of DGKCPDLKCYSGLIDY (SEQ ID NO: 87); (b) a VL region comprising
(i) a VL CDR1 region comprising the amino acid sequence of RASQSVGGYLA (SEQ ID NO: 43);(ii) a VL CDR2 region comprising the amino acid sequence of DASKRAT (SEQ ID NO: 92);(iii) a VL CDR3 region comprising the amino acid sequence of HQRSSWPPLT (SEQ ID NO: 93); VII: (a) a VH region comprising
(i) a VH CDR1 region comprising the amino acid sequence of SXXGXH (SEQ ID NO: 95), SXXGIH (SEQ ID NO: 98), or SXYGMH (SEQ ID NO: 101);(ii) a VH CDR2 region comprising the amino acid sequence of VISXD YADSVRG (SEQ ID NO: 96) or VISXDGXNXHYADSVXG (SEQ ID NO: 99);(iii) a VH CDR3 region comprising the amino acid sequence of DGXCSXXXCYSGLXDY (SEQ ID NO: 100), EGRCIEEXCYSGQIDY (SEQ ID NO: 102), or DGXCPDXXCYSGLIDY (SEQ ID NO: 103); and (b) a VL region comprising
(i) a VL CDR1 region comprising the amino acid sequence of RASQSVGXYXA (SEQ ID NO: 111) or RASQSVGXYLA (SEQ ID NO: 114);(ii) a VL CDR2 region comprising the amino acid sequence of XASXRAT (SEQ ID NO: 112) or DASXRAT (SEQ ID NO: 115);(iii) a VL CDR3 region comprising the amino acid sequence of XQRXXWPPLT (SEQ ID NO: 113), HQRSXWPPLT (SEQ ID NO: 116), or QQRSXWPPLT (SEQ ID NO: 117).